Breast cancer is the most common malignancy among women in Poland and all over the world. Despite the development of modern therapies, cytostatics still play one of the main roles in treatment of this disease. Classic anthracyclines, besides unquestionable efficacy in this disease, have a disadvantageous toxicity profile. Therefore, until now, there has been a limitation in using these drugs in patients with cardiological conditions and in patients who had previously taken anthracyclines. That was the cause for the development of a less toxic form of drug, which is liposomal doxorubicin -being as effective as classic anthracycline it has reduced cardiotoxicity. This article presents the case of a patient with metastatic breast cancer, in whom, after treatment with classic doxorubicin, liposomal form was administered which caused regression of liver metastases. Moreover, during treatment with liposomal doxorubicin, there has been no evidence of heart impairment. Teaching with case studies: cardio-oncology
INTRodUCTIoN
Breast cancer is the most frequently diagnosed female cancer in the world and its incidence continues to grow in both developed and, recently, in developing countries, including Poland. Thanks to the evolution of new treatment methods as well as the improvement of the existing ones, a progressive decrease in breast cancer-related mortality has been observed for over 20 years now. Nevertheless, following lung cancer, it presently constitutes the second cause of death among women with solid tumours in the world [1, 2] .
Thanks to the advancement of screening procedures and the general patient awareness, breast cancer is now more and more frequently detected at an early stage of the disease advancement, when surgical treatment combined with radiotherapy and (depending on the biological subtype of the disease) possibly also with chemotherapy, hormonal therapy and molecular targeted therapy, permits long-term progression-free survival or even complete recovery. Nonetheless, there is a group of patients in whom the disease is only detected at the stage of systemic dissemination or when it progresses to metastatic disease after adjuvant treatment. 80% of breast cancer patients are females over the age of 50, often with a tendency to develop abdominal obesity, which indicates cardiovascular comorbidities [3] . Such a patient profile, together with the fact that anthracyclines are the cytostatic drugs with the highest confirmed efficacy in breast cancer treatment, constitutes a significant problem and a serious challenge for contemporary oncologists [4] .
Balancing between the best possible therapeutic result and a safe dose of the medication proves very difficult at times. Despite numerous studies aimed at identifying cardiac injury predictors, such as the level of troponins and assessment of the heart in MRI, the determination of the ejection fraction by echocardiography remains the most common method in use [5, 6] . The method is not ideal, though. All of the above have prompted the researchers to search for safer forms of anthracyclines, such as pegylated or non-pegylated liposomal anthracyclines. Randomized clinical trials have indicated that non-pegylated liposomal doxorubicin is just as efficacious as the classical form of the drug, being safer at the same time [7, 8] . To date, its use has been limited to patients with metastatic breast cancer. However, clinical trials suggest that indications for use may be much broader, taking into consideration the fact that non-pegylated liposomal doxorubicin, compared to classical doxorubicin in adjuvant therapy, has been proven very beneficial in combination with e.g. herceptin and docetaxel [9] . Below we present a case of a patient in whom non-pegylated doxorubicin was administered for metastatic breast cancer, which allowed for significant regression of liver metastases.
CASe pReSeNTATIoN
In In 2010, during a regular follow-up visit, a reddened and thickened skin was observed at the post-operative scar site, which later turned out to be a local recurrence. Thanks to the chest and abdomen CT, the presence of metastatic lesions was excluded;
radical resection was performed, followed by radiotherapy. The treatment was made complete with non-steroid aromatase inhibitors.
Letrozole treatment was continued until November 2012. organ competence, prior treatment, and patient preferences [11] .
Anthracyclines are one of the high-activity drugs in breast cancer, and as such should be considered for first-line chemotherapy [11, 12] . As there were no contraindications in our patient, no cardiovascular conditions, and anthracyclines had not been previously 
